<DOC>
	<DOCNO>NCT01186796</DOCNO>
	<brief_summary>Participants ask take part research study learn growth hormone ( GH ) level decline estrogen production fall time menopause . GH hormone release pituitary gland affect bone , muscle , fat . Estrogen female hormone . Doctors believe low estrogen one reason GH diminishes postmenopausal woman . However , estrogen fall completely . This raise question whether little bit estrogen leave anything . Lack GH make bone thinner , muscle weak , fat store large . To learn whether low amount body 's estrogen maintain GH secretion menopause , investigator need stop estrogen might take partially block effect , , estrogen . The investigator use new estrogen-blocking drug ( fulvestrant ) . Fulvestrant ( also go tradename , Faslodex ) recently approve Food Drug Administration ( FDA ) treat breast cancer . Fulvestrant use non-FDA approved manner study ( treat breast cancer , study effect Growth Hormone secretion ) . The drug interfere estrogen work body , except brain . The study consider test whether estrogen work outside brain maintain GH secretion postmenopausal woman . This concept important , brain control pituitary gland secrete GH .</brief_summary>
	<brief_title>Role Endogenous Estrogen Growth-Hormone Regulation Postmenopausal Women</brief_title>
	<detailed_description>Hypotheses : Endogenous estrogen concentration contribute significantly maintain postmenopausal growth-hormone ( GH ) secretion ; ( b ) systemic vis-Ã -vis CNS action endogenous estrogen differentially control outflow somatotropic hormone ( viz. , GH , IGF-I , IGFBP-1 ) . Approach : contrast regulation GH axis postmenopausal woman pretreated CNS-excluded selective estrogen-receptor antagonist , fulvestrant , versus placebo . Background : fulvestrant release recently FDA therapy estrogen-sensitive postmenopausal breast cancer . The drug act mechanistically novel inhibitor estradiol-receptor dimerization , thereby deplete nuclear estrogen receptor . Fulvestrant gain access CNS . Thus , inhibition estrogen action restrict non hypothalamic site GH-axis control , pituitary gland , liver fat cell . In contrast , endogenous estrogen access CNS peripheral site . Premise : selective blockade peripheral estradiol receptor reduce GH secretion endogenous estrogen maintain GH secretion via systemic effect .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>healthy postmenopausal woman ( age 50 80 ) , wherein menopause define absence spontaneous menses 1 serum concentration FSH &gt; 30 IU/L ( ultrasensitive ) estradiol &lt; 20 pg/mL verify medical history screen blood work ; normal hemoglobin &gt; 11.0 g/dL woman ( ferritin level drawn , must normal , Hgb 11.0 11.5 ) , Platelets great 200 x 109/L , AST 848 U/L . Subjects ( age 50 ) screen baseline ECG record past year . exposure psychotropic neuroactive drug within five biological half life ; undesirability , disinclination ill advisability withhold estrogen supplement ( e.g . treatment symptomatic hot flush ; primary physician recommendation ) ; BMI &lt; 19 &gt; 35 drug alcohol abuse ; psychosis , depression , mania anorexia nervosa ; acute chronic organ systemic inflammatory disease ; endocrinopathy , primary thyroidal failure receive replacement ; although fulvestrant know intrinsic estrogenicity , safety reason include contraindication shortterm estrogen exposure ; e.g. , estrogensensitive neoplasia , undiagnosed vaginal bleeding , deepvenous thrombosis , stroke threaten stroke , clinical evidence atherosclerotic heart disease , include myocardial infarction and/or angina , refractory high blood pressure , severe type IV hyperlipidemia : nightshift work recent transmeridian travel ( exceed 3 time zone within 5 day admission ) ; systemic anticoagulation anti platelet therapy ( view i.m . injection fulvestrant ) ; history bleed diathesis ( ie ; disseminate coagulation ( DIC ) , clot factor deficiency acute weight change ( &gt; 3 kg 6 week ) ; and/or unwillingness provide write informed consent . Platelets le 200 x 109 /L International normalization ratio ( INR ) ( Prothrombin time ) great 1.6 Total bilirubin great 1.5 x ULRR ALT AST great 2.5 xULRR demonstrable liver metastasis great History hypersensitivity active inactive excipients fulvestrant ( ie ; castor oil Mannitol ) .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Women</keyword>
	<keyword>Fulvestrant Study</keyword>
	<keyword>Post Menopausal Women</keyword>
	<keyword>Hormones</keyword>
	<keyword>Healthy Adult Women</keyword>
</DOC>